All other participants adhered to the study protocol follow-up schedule. Postintervention liver biopsy was completed in 28 of 31 (90%) participants, 18 of 21 (86%) in the lifestyle intervention group and 10 of 10 (100%) in the control group. The reasons for the lack of follow-up biopsy were anticoagulation therapy (n = 1), technical difficulty (n = 1), and withdrawal from the study (n = 1). The mean weight change over the 48-week period was −8.7 kg (95% CI, −11.7 to −5.6) in the lifestyle intervention group as compared with −0.5 kg (95% CI, −4.8 to 3.8) in the control group (P = 0.005) (Table 2). Percent weight reduction (standard

deviation [SD]) of participants in the lifestyle group was significantly greater than that in participants in the control group at 24 weeks (8.9 [6.3]% versus 0.1 [3.7]%, P < ICG-001 concentration 0.001) and at 48 weeks (9.3 [7.5]% versus 0.2 [6.1]%, P = 0.003) (Fig. 2A) Eight participants (40%) in the lifestyle intervention group achieved a 10% or greater weight reduction, whereas no participant (0%) in the control group achieved this degree of weight reduction (P = 0.02). There was a nonsignificant trend for greater percent weight reduction in participants without underlying diabetes (n = 16) compared with those with diabetes (n = 14) (8.5 [9.5]% versus 3.8 [5.7]%, P = 0.12), and in participants who were not on metformin (n = 21) compared with those on

metformin (n = 9) (8.1 [8.4]% versus 2.1 [6.3]%, P = 0.07). A subgroup analysis within the lifestyle intervention group, after correction for heterogeneity of variance, found greater percent weight reduction (P = 0.01) for those without diabetes (13.6 [8.3]%) Dasatinib price versus those with diabetes (5.1 [3.1]%), and also for those not using metformin (11.4 [7.9]%) versus those using metformin (4.4 [3.1]%). There

was no significant difference in the degree of weight loss among participants who had baseline overweight (BMI, 25–29.9 kg/m2), class I (BMI 30–34.9 kg/m2), or class II obesity (BMI, 35–40 kg/m2). Participants in the lifestyle intervention group who had baseline overweight, class I and class II obesity lost 8.7 (6.3)%, 11.5 (7.1)%, and 6.9 (9.3)% of their body weight, respectively (P = 0.56). The mean waist circumference change over the 48-week period was −7.4 cm (95% CI, −10.3 to −4.6) in the lifestyle MCE intervention group as compared with +0.3 cm (95% CI, −3.2 to 3.8) in the control group (P = 0.004). The overall disease activity of nonalcoholic steatohepatitis (NAS [SD]) improved significantly in the lifestyle intervention group (−2.4 [1.6]) in comparison with the control group (−1.4 [2.1]) (P = 0.05) (Table 3). Steatosis score also improved to a significantly greater degree in the lifestyle group as compared with the control group (−1.1 [0.8] versus −0.3 [0.8], P = 0.02). Ballooning injury score improved in both groups, whereas fibrosis score did not change in either group.